Key Takeaways Hologic's buyout of up to $79 per share offers just 0.6% upside from recent levels.Align Technology hit $4B revenues in 2025, with aligner volumes rising 6.7% globally.DSO growth and digital tools adoption are boosting Align Technology's long-term expansion.Hologic (HOLX) and Align Technology (ALGN) are two well-established players in the medical technology (MedTech) market, each with distinct niche. Hologic develops diagnostics, surgical, and medical imaging technologies to advance women’s he ...

Key Takeaways Hologic's data reveals rising rates of women screened for blood pressure, cancer and diabetes.Hologic finds STI testing stagnant at 10%, with no improvement in five years.Hologic expands molecular diagnostics with Aptima tests for STIs and HPV.Hologic’s (HOLX) fifth edition of the Global Women’s Health Index highlights a persistent screening gap for key preventable conditions. Developed in partnership with Gallup, the Index tracks progress in women’s health and well-being worldwide, based on a ...

Key Takeaways Hologic shareholders approved Blackstone & TPG's take-private deal at up to $79/share.Hologic's Diagnostics revenues fell 2.7%, with molecular tests and Asia-Pacific sales under pressure.HOLX trades near its buyout price and at a premium versus peers, limiting upside potential.Hologic (HOLX) closed yesterday’s trading session at $75.05, down 0.1% from the previous close. The stock now sits nearly 1.2% below the buyout cash offer of $76 per share from Blackstone & TPG. Announced in October 2025 ...

With a market cap of $16.8 billion, Hologic, Inc. (HOLX) is a global medical technology company focused on developing and supplying diagnostic products, medical imaging systems, and surgical solutions for women’s health. It operates through four main segments: Diagnostics, Breast Health; GYN Surgical; and Skeletal Health, offering a wide range of tools for early detection, diagnosis, and treatment. Companies valued at $10 billion or more are generally labeled as “large-cap” stocks, and Hologic fits this ...

Core Insights - Hologic (HOLX) is projected to hold over 18% of the global women's health devices market by 2025, with the market expected to grow at a CAGR of 10.2% from 2026 to 2035, driven by increasing gynecological disorders, preventive healthcare awareness, and demand for minimally invasive solutions [1][8] Company Performance - Hologic's GYN Surgical unit has shown consistent performance, with surgical revenues reaching $180.8 million in Q1 FY26, reflecting a 7.5% year-over-year increase in constant currency, primarily due to higher sales of MyoSure and Fluent devices, as well as the Gynesonics acquisition [2][8] - The company has expanded its business through internal product development and acquisitions, enhancing its sales network [2] Market Expansion - Hologic's investments in commercial and market access capabilities have significantly increased the reach of its minimally invasive surgical products, with MyoSure gaining more market share internationally than in the U.S., indicating strong demand in untapped markets for treatments of uterine polyps and fibroids [3] - The addition of the Acessa laparoscopic fibroid removal system complements MyoSure by addressing larger fibroids [3] - NovaSure has shown consistent double-digit international growth, and the Sonata system was added through the Gynesonics acquisition, allowing treatment of symptomatic uterine fibroids [4] Competitive Landscape - Hologic faces competition from Medtronic (MDT) and Johnson & Johnson (JNJ), both of which offer comprehensive surgical solutions [5] - Medtronic has recently launched its FDA-cleared Hugo robotic-assisted surgery system, expanding into gynecologic and general surgery procedures [5] - Johnson & Johnson's Surgery portfolio includes a variety of surgical products for open, laparoscopic, and robotic procedures, with recent launches in its aspiration-first stroke portfolio [6] Stock Performance and Valuation - Hologic shares have increased by 20.7% over the past year, contrasting with a 3.8% decline in the industry [7] - The stock is currently trading at a forward 12-month price-to-sales (P/S) ratio of 3.88X, which is above its median but lower than the industry average, and carries a Value Score of C [9]

Core Insights - Hologic (HOLX) reported Diagnostics revenues of $464.4 million in Q1 of fiscal 2026, reflecting a 1.3% decline from the previous year, primarily due to decreased sales of COVID-19 tests and legacy sexually transmitted infections (STI) assays [2][9] - The company is focusing on expanding its diagnostics menu, particularly through stronger sales of BV and CV/TV tests, as well as Panther Fusion assays [3][9] - Recent FDA approvals for the Aptima HPV Assay and expanded CE marking for the Genius Digital Diagnostics System are expected to enhance Hologic's growth prospects [5][9] Diagnostics Revenue Performance - Molecular Diagnostics revenues fell by 3.5%, driven by weaker sales in COVID-19 and STI tests [2] - The decline was partially mitigated by increased sales in BV and CV/TV tests, alongside the Panther Fusion assays [3] - The company is targeting the U.S. vaginitis market to drive awareness and reimbursement for its high-throughput offerings [3] Product Developments - Hologic secured FDA 510(k) clearance and CE-IVDR marking for the Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays, supporting its strategy for menu diversification [3] - The Genius Digital Diagnostics System, which utilizes AI for detecting pre-cancerous lesions, is anticipated to be a significant growth driver [4] Competitive Landscape - Becton, Dickinson and Company (BDX) received CE Mark for the Revello Vascular Covered Stent, addressing a significant health issue in the EU [6] - Abbott (ABT) gained FDA approval for the CardioMEMS HERO, enhancing heart failure management, and secured CE Mark for the TactiFlex Duo Ablation Catheter [7] Stock Performance and Valuation - Hologic shares increased by 17.4% over the past year, contrasting with a 4.2% decline in the industry [8] - The company is currently trading at a forward five-year price-to-sales (P/S) ratio of 3.88X, which is lower than both its median and the industry average [10]

Industry Overview - The medical imaging industry is experiencing growth due to the increasing prevalence of chronic diseases, a rising geriatric population, and a focus on early and accurate diagnosis, with a projected CAGR of 6.65% through 2034 from $46.9 billion in 2026 [1] - Major companies in this sector, such as Hologic (HOLX) and GE HealthCare (GEHC), are attracting investor attention [1] Hologic (HOLX) Analysis - Hologic has developed multiple growth drivers through internal innovation and acquisitions, with Breast Health revenues increasing by 1.8% year over year in Q1 fiscal 2026, driven by Endomagnetics products [3] - GYN Surgical revenues rose by 8.7%, attributed to higher sales of MyoSure and Fluent devices, as well as the acquisition of Gynesonics [3] - However, Molecular Diagnostics revenues declined by 3.5% due to lower sales of COVID-19 tests and legacy assays, although growth in certain assays partially offset this decline [4] - Hologic ended Q1 with cash and cash equivalents of $2.17 billion and an adjusted net leverage ratio of 0.3X, and received FDA approval for its Aptima HPV Assay [5] - Hologic agreed to a buyout by Blackstone and TPG valued at up to $18.3 billion, offering shareholders $76 per share in cash, with a total potential value of $79 per share, indicating a 46% premium [6] GE HealthCare (GEHC) Analysis - GE HealthCare reported strong performance in Q4 2025, with double-digit organic revenue growth in Pharmaceutical Diagnostics and mid-single-digit growth in Imaging and Advanced Visualization Solutions, ending with a record backlog of $21.8 billion [7] - The company signed significant agreements, including a 7-year deal with the University of Rochester Medical Center, and plans to acquire Intelerad to enhance cloud-enabled imaging [8] - GEHC's D3 strategy focuses on using smart devices and digital tools for precision care, with new products contributing nearly 55% of revenues [10] - The company anticipates an increase in service agreement capture rates due to new innovations and has improved its business system, Heartbeat, leading to better sales and cash conversion [11] - Recent FDA clearances for new MR innovations and collaborations to advance AI in fetal ultrasound assessments further strengthen GEHC's position [12] Earnings Projections - The Zacks Consensus Estimate for Hologic's fiscal 2026 earnings indicates a 4.9% year-over-year growth to $4.47, with mixed estimate movements in the past 60 days [13] - For GE HealthCare, the earnings estimate for 2026 shows an 8.7% year-over-year growth to $4.99, with upward revisions in the last 60 days [14] Price Performance & Valuation - Hologic shares have increased by 0.7% over the past three months, while GE HealthCare shares have gained 4.2% [15] - Hologic trades at a forward price-to-sales (P/S) ratio of 3.87X, lower than its median, whereas GE HealthCare trades at a P/S of 1.76, in line with its median [16] Investment Outlook - Hologic's recent quarter performance was impacted by lower COVID testing and legacy STI test sales, with minimal upside potential from the buyout offer, suggesting current shareholders may consider exiting [19] - In contrast, GE HealthCare's strong segment performance and innovation strategy present it as a compelling investment opportunity, with bullish earnings projections [20]

Core Insights - Hologic's $18.3 billion acquisition by Blackstone and TPG is nearing completion, marking the largest medical devices deal in two decades, with 99.8% of shareholders approving the proposal [1][2] - The acquisition price of $76 per share, plus a contingent value right (CVR) of up to $3, represents a 46% premium over the stock price before the deal was announced [2] - Hologic's recent quarterly results showed a 2.5% year-over-year revenue increase but missed analyst expectations, particularly in Breast Health sales [5][6] Acquisition Details - Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash, with a potential additional $3 per share based on future revenue goals [2] - The total purchase price could reach $79 per share, indicating a 46% premium compared to the last trading day before acquisition rumors [2] - The stock is currently trading close to the buyout price, suggesting limited upside potential for existing shareholders [3][7] Financial Performance - Hologic reported first-quarter revenues of $1,047.8 million, a 2.5% increase year-over-year, but fell short of analyst forecasts [5][6] - Breast Health product revenues decreased by 2.2%, attributed to lower sales of digital mammography systems and related products [7] - GYN Surgical revenues increased by 8.7%, driven by higher sales from the acquired Gynesonics business [9] Market Position and Valuation - Hologic's shares have gained 1.2% over the past three months, outperforming the industry, which declined by 7.7% [14] - The company is trading at a forward Price-to-Sales (P/S) ratio of 3.86, higher than its historical median of 3.49 and the sector average of 2.24 [16] - Compared to competitors, Hologic's valuation appears elevated, with GE HealthCare and Medtronic trading at lower P/S ratios [16] Regulatory Developments - Hologic's Aptima HPV Assay received FDA approval for primary screening, expanding its cervical cancer screening offerings [12] - The approval follows extensive real-world studies involving over 650,000 women, enhancing the company's market position in cervical cancer diagnostics [12][13]

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Company Overview - Hologic, Inc. (HOLX) is a global medical technology company with a market cap of $16.7 billion, focused on improving women's health through early disease detection and treatment [1] - The company develops and supplies diagnostic assays, medical imaging systems, and surgical solutions across its Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments [1] Stock Performance - Over the past 52 weeks, HOLX shares have increased by 16.2%, outperforming the S&P 500 Index, which gained 15.6% [2] - Year-to-date, HOLX stock has risen marginally, lagging behind the S&P 500's 1.7% return [2] - HOLX shares have outpaced the State Street Health Care Select Sector SPDR ETF (XLV), which returned 6.8% over the same period [3] Recent Financial Results - Following Q1 2026 results released on January 29, shares of Hologic fell marginally; adjusted EPS was $1.04 and revenue totaled $1.05 billion, both below expectations [5] - The decline in investor sentiment was attributed to weakness in Diagnostics revenue, margin compression due to $15.3 million in tariff-related costs, and the lack of forward guidance due to a pending acquisition by Blackstone and TPG [5] Future Earnings Expectations - For the fiscal year ending in September 2026, analysts expect HOLX's adjusted EPS to grow by 4.9% year-over-year to $4.47 [6] - The company's earnings surprise history is mixed, having topped consensus estimates in three of the last four quarters while missing on one occasion [6] - Among the 18 analysts covering the stock, the consensus rating is a "Hold" [6] Price Target - The mean price target for HOLX is $75.58, representing a marginal premium to its current price [8] - The highest price target of $79 suggests a potential upside of 5.3% [8]